Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

ted final results from its Phase Ib study of bavituximab in patients with chronic HCV infection. Bavituximab appeared generally safe and well tolerated and there were signs of anti-viral activity at all dose levels tested.

-- In October 2007, Peregrine announced that the first patient had been dosed in a clinical trial designed to evaluate the safety and pharmacokinetics of bavituximab in patients co-infected with HCV and HIV. Patient cohorts are receiving ascending doses of bavituximab. HCV and HIV viral titers and other biomarkers are being evaluated.

-- In August 2007, Peregrine announced that the first GBM brain cancer patient had been administered Cotara in a Phase II clinical trial designed to evaluate its safety and efficacy. The study's primary objective is to confirm the maximum tolerated dose of Cotara and secondary objectives include estimates of overall patient survival, progression free survival and the proportion of patients alive at six months.

-- In June 2007, Peregrine announced commitments to purchase $22.5 million in shares of its common stock in a registered direct offering, for net proceeds of approximately $20.9 million. The financing did not include warrants.

Conference Call

The company will host a conference call today, July 14, 2008 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its fiscal year 2008 financial results.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the concl
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... CA (PRWEB) July 29, 2014 ... medical devices, and cloud based eClinical technologies, have been ... Device Online. These follow a long line of white ... profile publications including Life Science Leader, Pharmaceutical Online, and ... Clinovo provided a paper by CTO Marc Desgrousilliers, ...
(Date:7/28/2014)... Reston, VA (PRWEB) July 28, 2014 ... leading nonprofit authority on the use of health IT ... its Health Plan Identifier (HPID) Workgroup has ... Between a Health Plan and Payer?” The HPID Workgroup, ... worked closely with the Centers for Medicare and Medicaid ...
(Date:7/28/2014)...   JOLT , a leading technology accelerator, announced today ... portfolio of startups. Next-level tech and boundary-pushing innovation have ... accelerator, and Cohort four is no exception, with six ... its launch in July 2012, JOLT has produced 17 ... at 23 investments, JOLT,s portfolio has an overall mix ...
(Date:7/28/2014)... 28, 2014 Appistry, Inc. , ... bring the power of genomics to next-generation medicine, announced ... Pipeline Challenge . , Two Appistry staff will ... National Center for Genome Resources, and Mr. Neil Miller, ... of Kansas City. Rounding out the panel are Appistry’s ...
Breaking Biology Technology:Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... at the helm of several companies, Michael Flavin, CEO of ... Ill. across from Argonne National Laboratory ), sees a ... , ,Following a six-month preparation period, Flavin says hell ... financial adviser Legg Mason to raise about $30 ...
... - Automating Peripherals Inc announced that the company's ... standards mandated by the Health Insurance Portability and ... on Accreditation of Healthcare Organizations (JCAHO). SecurALL is ... regulate and monitor facility access throughout an organization ...
... Pilots of F-18s have been using the technology for years ... Soon, automobile drivers will get a similar view with speed, ... their windshield. The goal of the heads-up display is to ... , ,"For many of the distractions that can lead to ...
Cached Biology Technology:Advanced Life Sciences to Hit the Road For $30 Million in Funding 2Advanced Life Sciences to Hit the Road For $30 Million in Funding 3Advanced Life Sciences to Hit the Road For $30 Million in Funding 4
(Date:7/28/2014)... tool that can help advance the genetic engineering ... bioenergy, has been developed by researchers with the ... (JBEI), a multi-institutional partnership led by Lawrence Berkeley ... developed an assay that enables scientists to identify ... critical components in the biosynthesis of plant cell ...
(Date:7/28/2014)... to prevent and treat HIV infection has been problematic ... molecules can arouse as they get rid of the ... Weizmann Institute and the National Institutes of Health (NIH) ... interferons around the time of infection could ... Their research appeared in Nature . , ...
(Date:7/28/2014)... at Harvard University today announced that its human ... formed private company to accelerate development of pharmaceutical, ... The announcement follows a worldwide license agreement between ... start-up Emulate Inc., relating to the use of ... "This is a big win towards achieving our ...
Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Interfering with interferon 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3
... IOF Medal of Achievement was awarded today at the ... A. Kanis. The award honours an individual ... through original and outstanding scientific work. It underlines an ... and awareness of osteoporosis and to promote medical innovation, ...
... of the Walter and Eliza Hall Institute from 1996-2009 ... the institute,s Molecular Genetics of Cancer division. The ... Doug Hilton, said he was delighted Professor Cory had ... are immensely proud of this latest of Suzanne,s achievements," ...
... -- With thousands of scientists across the globe searching for ... a growing emphasis on finding the "master regulators" that guide ... and the University of Cambridge suggests that a closely connected ... cells (HSCs), the self-renewing cells the body uses to make ...
Cached Biology News:Suzanne Cory becomes first-elected woman president of AAS 2Stem cells: In search of a master controller 2
Sf21 Insect Cells (Frozen) in Max-XP Medium...
... system, 220-240 V, uses floating pin printing ... lipids, and other biomolecules onto a variety ... can generate high-density arrays with greater than ... than 57,000 spots per membrane with a ...
Freeze 'N Squeeze DNA gel extraction spin columns use a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. Supplied as 25 columns....
... Storage: The kit is stable for 12 months ... contents of the kit cold. , ,Principle: ... silica-gel based membrane which selectively adsorbs up to ... specialized binding buffers. Nucleotides, oligos ( , ,Application: ...
Biology Products: